Anesiva, Inc. (ANSV)

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was founded in 1999 and is headquartered in South San Francisco, California.

For the six months ended 30 June 2006, Anesiva Inc. reported no revenues. Net loss increased 90% to $28.4M. Revenues reflect that the Company had no contract revenues. Higher loss reflects a rise in research & development expenses due to an inclusion of stock based compensation, higher general & administrative expenses due to increased legal, consulting & other corporate expenses and the inclusion of interest expense.